EGFR and non-small cell lung carcinoma: This phase II study in patients with previously treated NSCLC with wild type EGFR revealed that the combination therapy of erlotinib and S-1 was not feasible, and the enrollment was stopped, following the recommendation of the Safety Review Committee based on two TRDs.